In summary, there is good evidence that anti-CTLA-4 mabs have two separate routes to achieving productive cancer immunotherapy, either via TREG depletion (Figure 1) or simple blockade of sCTLA-4 or the CTLA-4 receptor (Figure 2). This evidence concerns the gene CTLA4 and cancer.